192 related articles for article (PubMed ID: 32600534)
1. Management of Metastatic Renal Cell Carcinoma with Variant Histologies.
Flippot R; Damarla V; McGregor BA
Urol Clin North Am; 2020 Aug; 47(3):319-327. PubMed ID: 32600534
[TBL] [Abstract][Full Text] [Related]
2. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.
Alhalabi O; Karam JA; Tannir NM
Curr Opin Urol; 2019 Sep; 29(5):521-525. PubMed ID: 31305271
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma.
Westerman ME; Shapiro DD; Wood CG; Karam JA
Urol Clin North Am; 2020 Aug; 47(3):329-343. PubMed ID: 32600535
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for the Management of Rare Kidney Cancers.
Giles RH; Choueiri TK; Heng DY; Albiges L; Hsieh JJ; Linehan WM; Pal S; Maskens D; Paseman B; Jonasch E; Malouf G; Molina AM; Pickering L; Shuch B; Srinivas S; Srinivasan R; Tannir NM; Bex A
Eur Urol; 2017 Dec; 72(6):974-983. PubMed ID: 28720391
[TBL] [Abstract][Full Text] [Related]
5. The use of cytoreductive nephrectomy in patients with renal cell carcinoma.
Ghandour RA; Singla N; Margulis V
Expert Rev Anticancer Ther; 2019 May; 19(5):405-411. PubMed ID: 31020871
[TBL] [Abstract][Full Text] [Related]
6. Current status of prognostic factors in patients with metastatic renal cell carcinoma.
Teishima J; Inoue S; Hayashi T; Matsubara A
Int J Urol; 2019 Jun; 26(6):608-617. PubMed ID: 30959579
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma.
Shinohara N; Abe T
Int J Urol; 2015 Oct; 22(10):888-97. PubMed ID: 26147084
[TBL] [Abstract][Full Text] [Related]
8. The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.
Zhang T; Hwang JK; George DJ; Pal SK
Cancer Treat Res Commun; 2020; 24():100183. PubMed ID: 32563923
[TBL] [Abstract][Full Text] [Related]
9. [Why have tyrosine kinase inhibitors failed in the adjuvant situation and do checkpoint inhibitors make more sense?].
Krege S
Urologe A; 2020 Feb; 59(2):149-154. PubMed ID: 32076796
[TBL] [Abstract][Full Text] [Related]
10. Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review.
Di Stefano RF; Buttigliero C; De Luca E; Reale ML; Pisano C; Leone G; Zichi C; Massa F; Manfredi M; Vignani F; Bollito E; Porpiglia F; Di Maio M; Tucci M
Clin Genitourin Cancer; 2018 Dec; 16(6):e1087-e1090. PubMed ID: 30122516
[No Abstract] [Full Text] [Related]
11. Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma.
Reed JP; Posadas EM; Figlin RA
Expert Rev Anticancer Ther; 2019 Mar; 19(3):259-271. PubMed ID: 30669895
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
[TBL] [Abstract][Full Text] [Related]
13. Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment.
Tomita Y
Int J Urol; 2016 Jan; 23(1):13-21. PubMed ID: 26347163
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors.
Biles MJ; Patel HD; Allaf ME
Urol Clin North Am; 2020 Aug; 47(3):359-370. PubMed ID: 32600537
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies for non-clear renal cell carcinoma.
Singer EA; Bratslavsky G; Linehan WM; Srinivasan R
Target Oncol; 2010 Jun; 5(2):119-29. PubMed ID: 20680492
[TBL] [Abstract][Full Text] [Related]
16. Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC-Registry.
Staehler M; Goebell PJ; Müller L; Emde TO; Wetzel N; Kruggel L; Jänicke M; Marschner N;
Int J Cancer; 2020 Mar; 146(5):1307-1315. PubMed ID: 31498894
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered.
Stewart GD; Aitchison M; Bex A; Larkin J; Lawless C; Méjean A; Nathan P; Oades G; Patard JJ; Paul J; Ravaud A; Escudier B;
Eur Urol; 2017 Jun; 71(6):845-847. PubMed ID: 27815086
[TBL] [Abstract][Full Text] [Related]
18. The evolving role of cytoreductive nephrectomy: incorporating genomics of metastatic renal cell carcinoma into treatment decisions.
Mano R; Gopal N; Hakimi AA
Curr Opin Urol; 2019 Sep; 29(5):531-539. PubMed ID: 31313716
[TBL] [Abstract][Full Text] [Related]
19. TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery.
Verzoni E; Ratta R; Grassi P; Salvioni R; Stagni S; Montone R; Fucà G; Cappelletti V; Reduzzi C; De Giorgi U; Procopio G
Tumori; 2018 Oct; 104(5):401-405. PubMed ID: 29192741
[TBL] [Abstract][Full Text] [Related]
20. Evolving Role of Urologists in the Management of Advanced Renal Cell Carcinoma.
Kapoor A; Kim J; Goucher G; Hoogenes J
Urol Clin North Am; 2020 Aug; 47(3):271-280. PubMed ID: 32600530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
